|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00004293 |
|
Date of registration:
|
18/10/1999 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
November 1999 |
|
Target sample size:
|
24 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00004293 |
|
Study type:
|
Interventional |
|
Study design:
|
Primary Purpose: Treatment
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
John Barranger |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Pittsburgh |
|
|
Name:
|
John Barranger |
|
Address:
|
|
|
Telephone:
|
412-624-4623 |
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Gaucher disease with glucocerebrosidase deficiency confirmed
by enzymatic or molecular assay At least 3 organ systems affected, based on the following
criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary
compromise Symptoms compromise daily activities or risk longevity No neurologic disease
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Gaucher's Disease
|
|
Intervention(s)
|
|
Drug: glucocerebrosidase
|
|
Secondary ID(s)
|
|
199/11725
|
|
UPITTS-M1230
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|